MTC 896

Drug Profile

MTC 896

Alternative Names: MTC896

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mimetica
  • Class Hormones; Skin disorder therapies
  • Mechanism of Action Melanocortin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 05 Dec 2017 Phase-II development for Acne vulgaris is ongoing in USA and Australia (Topical) (Mimetica website, December 2017)
  • 12 Jul 2017 Mimetica completes a phase II trial in Acne vulgaris (In volunteers) in Australia (Topical) (ACTRN12617000498392)
  • 03 May 2017 Phase-II clinical trials in Acne vulgaris (In volunteers) in Australia (Topical) (ACTRN12617000498392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top